Numerous clinical studies have suggested that the detection of PD-L1 expression or tumor mutation burden (TMB) should serve as a companion diagnostic (CDx) assay for individuals newly diagnosed with NSCLC. The gene discussed is CD274; the disease is non-small cell lung carcinoma.